Glutathione and Parkinson's disease: is this the elephant in the room?
about
Redox Imbalance and Viral Infections in Neurodegenerative DiseasesParkinson's disease as a result of agingParkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathyGlutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neuronsEvaluation of a dithiocarbamate derivative as a model of thiol oxidative stress in H9c2 rat cardiomyocytes.Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1Proteome analysis reveals roles of L-DOPA in response to oxidative stress in neuronsRegulation and function of selenoproteins in human diseaseAstrocytes and therapeutics for Parkinson's disease.An association study between Heme oxygenase-1 genetic variants and Parkinson's disease.Role of oxidative stress in Parkinson's disease.Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivoNon-invasive monitoring of L-2-oxothiazolidine-4-carboxylate metabolism in the rat brain by in vivo 13C magnetic resonance spectroscopy.Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human α-synucleinEnhanced glutathione efflux from astrocytes in culture by low extracellular Ca2+ and curcumin.Standardized extract of Withania somnifera (Ashwagandha) markedly offsets rotenone-induced locomotor deficits, oxidative impairments and neurotoxicity in Drosophila melanogaster.The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disordersX-ray absorption spectroscopy at the sulfur K-edge: a new tool to investigate the biochemical mechanisms of neurodegeneration.Neuroprotective effects of erucin against 6-hydroxydopamine-induced oxidative damage in a dopaminergic-like neuroblastoma cell line.Thiol-redox signaling, dopaminergic cell death, and Parkinson's diseaseNrf2--a therapeutic target for the treatment of neurodegenerative diseases.Safety survey of intranasal glutathione.Efficient GSH delivery using PAMAM-GSH into MPP-induced PC12 cellular model for Parkinson's disease.Glutathione dysregulation and the etiology and progression of human diseases.Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology.Oral administration of γ-glutamylcysteine increases intracellular glutathione levels above homeostasis in a randomised human trial pilot study.The putative multidrug resistance protein MRP-7 inhibits methylmercury-associated animal toxicity and dopaminergic neurodegeneration in Caenorhabditis elegansMechanisms of beta-N-methylamino-L-alanine induced neurotoxicity.Adaptation and sensitization to proteotoxic stress.Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.Motor complications, levodopa metabolism and progression of Parkinson's disease.Molecular biomarkers of lung carcinoma.Electrochemical determination of glutathione: a review.Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease.Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.Selenium biochemistry and its role for human health.The glutathione system: a new drug target in neuroimmune disorders.The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging.Mitochondrial mechanisms of redox cycling agents implicated in Parkinson's disease.Potential application of lithium in Parkinson's and other neurodegenerative diseases.
P2860
Q26750630-F09C683A-24AB-4EF1-8E3A-C5B08B2EF280Q28084395-2D6560C4-A686-4B3A-B05A-741E98B35CE7Q28475940-5D605E89-D1B9-4945-AAB9-2DBDA98D7906Q30498761-C88AB041-2738-4B74-BD67-E0EB78F95D42Q33572622-4ECC37F5-2318-4C0D-B79E-2224812E493AQ33646741-5263CE00-F259-4418-AD78-1EC782F3FFD3Q34017856-7F4465BE-1102-4E9F-8606-F83BE566337BQ34029071-E54124D5-FF98-4E94-9450-22544BD89A8CQ34168266-867C34FD-B95E-4213-81E7-76D0C0B4F15FQ34238382-17F5BE1A-DE6D-46C8-9D35-8C4046C942DCQ34339252-80948BF2-6974-4E46-BC6D-EB8807C2F15FQ34639246-F257CEFB-AD9F-4C43-BF25-E30AD0EF8BCFQ34717205-02CFC0E3-B827-4E78-999A-AE3EA5A11678Q34718257-6D37DBF0-7A5D-4F96-AEC6-873AF46A3186Q34989760-3EC0DD46-06D7-47C9-ADEB-23301E87AC8AQ35220841-7AB2843B-5F19-4DD2-9424-8A5B383BACE1Q35246024-BB6BB3C1-9A32-4BED-A286-66FA38DC1109Q36015551-419876B3-E0B7-418E-98F2-C907BB125675Q36321714-E089E52C-A17A-4833-8B52-01776EC219EEQ36326535-50D95152-A7A0-4D05-AD3F-919BD302D98EQ36732766-73FAC9C8-C36A-4201-9F65-56F25707E45DQ36836501-69551C49-5E32-452F-A69F-DD2129E2B09CQ37298397-5960DD97-68CD-4EC6-B203-03C7726DFF50Q37372896-FA167E71-2DE5-434C-9459-8A480101F550Q37494776-F0F8632E-8314-4CAB-80E3-3AE3E747E962Q37617099-7F407DE8-A21F-47EA-A6F1-D6344ED84AA6Q37633312-29A4B006-6BB9-4680-A342-5CE08D2AEB02Q37636167-14351838-C5EF-45EE-9F71-6B69E7916D18Q37651678-4B83FB19-0427-4F75-8416-791D6836A8A0Q37791469-C770E911-8EAF-4049-BF29-43A8867A7D0CQ37863681-8A87A58D-CD38-4AF0-9C88-9A665779CDE9Q37971659-EA93D458-36D0-499A-8E34-3849189558D6Q37998472-940ACF4C-24DF-4F77-AE60-CE6C954EDF66Q38112217-7C0A05E8-D6E1-47F3-94C2-5D343829BEACQ38148491-06BF87CC-3DB2-49B6-88AE-72AC4F0EBD82Q38159453-8406D327-74B5-48B8-857B-7C9071118E67Q38206126-2416DA5F-2C11-4B03-AF31-B71954533D98Q38242194-3FC3A23A-8A3B-41F1-881C-0FB7274B5CBEQ38370162-86F559E3-3F54-46E7-ABF6-AB85C52FDFF9Q38636753-EC010155-298B-4C03-8BD1-BF2E5763849B
P2860
Glutathione and Parkinson's disease: is this the elephant in the room?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glutathione and Parkinson's disease: is this the elephant in the room?
@en
Glutathione and Parkinson's disease: is this the elephant in the room?
@nl
type
label
Glutathione and Parkinson's disease: is this the elephant in the room?
@en
Glutathione and Parkinson's disease: is this the elephant in the room?
@nl
prefLabel
Glutathione and Parkinson's disease: is this the elephant in the room?
@en
Glutathione and Parkinson's disease: is this the elephant in the room?
@nl
P2093
P1476
Glutathione and Parkinson's disease: is this the elephant in the room?
@en
P2093
Gail D Zeevalk
Laura P Bernard
Roozbeh Razmpour
P304
P356
10.1016/J.BIOPHA.2008.01.017
P577
2008-03-14T00:00:00Z